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Background Post-procedural aortic regurgitation (AR)
negatively impacts the prognosis after trans-catheter aortic
valve implantation. However, data evaluating the impact of
different post-procedural AR grades (particularly mild) on
clinical outcomes are still important.
Aim and Methods A retrospective cohort analysis was
performed on all consecutive patients with severe aortic
stenosis who underwent trans-catheter aortic valve
implantation between July 2008 and August 2011 in a single
Institution. Aim of the study was to evaluate the impact of
different post-procedural AR grades on early and mid-term
clinical outcomes.
Results 322 consecutive patients were evaluated. At post-
procedural echocardiographic evaluation: 105 (32.6%)
patients had no AR, 204 (63.4%) mild AR and 13 (4%)
moderate/severe AR. In-hospital mortality was higher in
patients with moderate/severe AR than in those with absent
or mild AR (38.5% vs. 2.6%, P< 0.001). At a median clinical
follow-up of 342 days [interquartile range 93–485]
cardiovascular mortality was 2.9% in patients without AR;
13.2% in the mild AR group (PU0.004 vs. absent AR) and
46.2% in the moderate/severe AR group (P< 0.001 vs. mild
or absent AR). On multivariable analysis, post-procedural
AR (hazard ratioU2.65 absent vs. present any grade, 95%
confidence intervalU1.11–6.29; PU0.027) was an
independent predictor of mid-term mortality.
Conclusions The impact of post-procedural AR on
outcomes after trans-catheter aortic valve implantation is
proportional with its grade even in case of mild post-
procedural AR compared to absent. This study confirms
that every effort should be made to reduce the grade of
post-procedural AR after trans-catheter aortic valve
implantation with current devices.
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Introduction
Transcatheter aortic valve implantation (TAVI) is an
effective and worldwide practiced treatment option for
high-risk surgical patients with severe aortic stenosis.1,2
Although outcomes following TAVI have improved
through developments in technology and increasing
clinical experience, postprocedural aortic regurgitation
remains relatively common and an important issue as it
has been identified as an independent predictor of
mortality.3–5 Incongruence between device size and
aortic annulus dimensions,6,7 extensive calcification of
the aortic valve8–10 and prosthesis malposition11–13 are
considered the main causes of this phenomenon. Trivial
or mild postprocedural aortic regurgitation is actually
frequent,6,14–16 whereas moderate-to-severe is relatively
rare, but it may be associated with increased mortality
between 30 days and 1 year.3
In the present study, we sought to evaluate the natural
history and the impact of different postprocedural aortic
regurgitation grades on early and midterm clinical out-
comes in patients treated with either the self-expanding
CoreValve (Medtronic Inc., Minneapolis, Minnesota,
USA) or balloon-expandable Edwards SAPIEN (ESV-
Edwards Lifesciences, Irvine, California, USA) aortic
valve bioprosthesis.
Methods
A retrospective cohort analysis was performed on 344
consecutive patients with symptomatic severe aortic
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stenosis who underwent TAVI between July 2008 and
August 2011 at the San Raffaele Scientific Institute,
Milan, Italy. Patients undergoing TAVI for pure
aortic regurgitation or valve-in-valve procedures were
excluded. All patients referred for consideration of
TAVI underwent a systematic assessment including
transthoracic echocardiography (TTE), coronary angio-
graphy, aortography and iliofemoral angiography, com-
puted tomography scan of the heart, aorta and peripheral
vasculature, pulmonary function testing, carotid artery
ultrasonography and multidisciplinary evaluation by both
a cardiac surgeon and an interventional cardiologist.
Informed consent was obtained from each patient, and
the study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki as reflected in ‘a-priori’
approval by the institution’s human research committee.
Prespecified clinical and laboratory data were prospec-
tively collected for all patients on admission, immediately
after TAVI and during midterm follow-up. All patients
were followed up prospectively, and data on major
clinical events and complications during and after TAVI
were obtained from hospital documentation, whereas
data on events occurring after discharge were derived
from follow-up visits or by contacting patients by phone.
TTE or transesophageal echocardiography (TEE) with
evaluation of the aortic annulus diameter, aortic mean
gradient, aortic peak gradient and aortic valve area (AVA)
was performed at admission (preprocedure), discharge
and at 30-day, 6-month, 1-year and more than 1-year
follow-up visits by the same operator who performed the
prior examination.
Procedural details
Procedural details have already been described else-
where.17 In order to assess the grade of postprocedural
aortic regurgitation, an angiogram immediately after
transcatheter heart valve (THV) implantation (and
approximately 10min after CoreValve implantation in
case of moderate or severe postprocedural aortic regur-
gitation) and an intraprocedural TTE or TEE with an
established integrative approach for quantitative and
semiquantitative grading according to guidelines were
performed in all the patients.18 In the case of discrepancy
between aortography and echocardiography, we always
accepted the worst result as our evaluation of the aortic
regurgitation grade. In case of moderate-to-severe aortic
regurgitation, any countermeasure adopted (i.e. post-
dilatation, snaring or valve-in-valve implantation) was
left to the discretion of the operator.
Aortic regurgitation definition
The quantitative and semiquantitative hemodynamic
assessment of aortic regurgitation severity was performed
with Doppler echocardiography and aortography as per
guidelines.18–20 Aortic regurgitation grading was based on
color Doppler imaging through the assessment of the
height and width of the regurgitant jet. Short-axis and
long-axis TTE views were used to assess the severity of
the aortic regurgitation (absent, mild and moderate/
severe). According to the Valve Academic Research
Consortium (VARC),21 aortic regurgitation was graded
as being absent, mild, moderate or severe.
Endpoint definitions
The primary outcomes evaluated in the present study
were all-cause and cardiovascular mortality at follow-up.
All the procedural and clinical outcomes were adjudi-
cated internally with the VARC definitions.21
Statistical analysis
Continuous variables were expressed as mean standard
deviation, and qualitative variables as numbers and per-
centages. Comparisons of clinical, echocardiographic,
angiographic or procedure-related characteristics of
patients, according to presence of postdilatation and
different grades of aortic regurgitation, were performed
with either the Student’s t-test (continuous variables) or
chi-square statistic (categorical) as appropriate. A Bon-
ferroni test was used to correct for repeated testing when
three groups were analyzed. Exploratory multivariable
analysis by Cox regression was performed to evaluate the
predictors of midterm mortality following TAVI. The
variables entered into the initial multivariable model
included body mass index (BMI), Society of Thoracic
Surgeons (STS) score, left ventricular ejection fraction
(LVEF), postprocedural aortic regurgitation, renal fail-
ure, logistic EuroSCORE, angina and peripheral vascular
disease. Our multivariable model testing used the pur-
poseful selection of covariates strategy as proposed by
Hosmer and Lemeshow, and thus our final model was
obtained. Survival analyses were performed by Kaplan–
Meier analysis. All analyses were conducted using SPSS
software, version 18.0, and all reported P-values are two-
sided. P-values <0.05 were regarded as statistically
significant.
Results
Between July 2008 and August 2011, a total of
344 patients underwent a TAVI procedure. Among
these, 22 patients [16 patients treated for bioprosthetic
valve degeneration (‘valve-in-valve’) and 6 patients for
‘isolated’ severe aortic regurgitation] were excluded from
the final analysis. Thus, a total of 322 patients constituted
the cohort of the present study. Baseline clinical, echo-
cardiographic and angiographic characteristics were com-
pared according to the grade of postprocedural aortic
regurgitation, which was defined as absent, mild and
moderate/severe (Tables 1 and 2). Overall mean patient
age was 79.6 7 years. New York Heart Association class
III/IV was present in 214 (66.9%) patients, whereas 46
(14.3%) had a severely reduced (<40%) LVEF. Conco-
mitant coronary artery disease was present in 140 (44.3%)
patients, and 71 (22%) patients underwent previous
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coronary artery bypass graft. Mean logistic EuroSCORE
was 24.0 16.9%, whereas mean STS score was 9.5 9.3.
Mean AVA was 0.76 0.5 cm2. Mean aortic annulus
diameter was 22.9 3.1, 23.1 4.1 and 22.6 3.0mm
at computed tomography scan, TEE and TTE evalu-
ation, respectively. At baseline, 247 (78.3%) patients were
free from aortic regurgitation. Immediately after TAVI,
aortic regurgitation was classified as absent in 105 (32.6%)
patients, mild in 204 (63.4%) patients and moderate-to-
severe in 13 (4%) patients. No significant differences
were noted among patients grouped according to post-
procedural aortic regurgitation grade (absent, mild
and moderate/severe) with regard to baseline clinical
characteristics with the exception of AVA (aortic regur-
gitation absent: 0.8 0.22 cm2; mild aortic regurgitation:
0.69 0.21 cm2; moderate/severe aortic regurgitation:
0.65 0.13 cm2; P¼ 0.003) and left ventricular end-
diastolic diameter (aortic regurgitation absent:
50.5 6.3mm; mild aortic regurgitation: 52.9 7.9mm;
moderate/severe aortic regurgitation: 56.5 9.5mm;
P¼ 0.035), which were, respectively, smaller and larger
in patients with moderate/severe postprocedural aortic
regurgitation.
Procedural characteristics are shown in Table 3. Of the
322 TAVI procedures, 261 (81.1%) were performed trans-
femorally, 34 (10.6%) through a transaxillary access, 24
(7.4%) transapically and 3 (0.9%) through the direct aortic
route. The CoreValve was implanted in 128 (39.8%)
patients whereas the Edwards SAPIEN or SAPIEN
XT was implanted in 194 (60.2%) patients. Procedural
success was achieved in 96% of patients. The mean
transaortic pressure gradient decreased from
53.3 15.0mmHg (preprocedure) to 9.8 4.7mmHg
(postprocedure, P< 0.001). THV postdilatation was per-
formed in 61 (18.9%) patients: 14 (7.2%) with the
Edwards SAPIEN and 47 (36.7%) with the CoreValve
(P< 0.0001).
In-hospital mortality
In-hospital death occurred in 13 (4.0%) patients. Causes
of in-hospital death are shown in Table 4. Death rates
were significantly higher in patients with moderate/
severe postprocedural aortic regurgitation than in those
with absent or mild aortic regurgitation (38.5 vs. 2.6%,
P< 0.001). There was no significant difference between
patients with absent aortic regurgitation and those with
mild aortic regurgitation (1 vs. 3.4%, P¼ 0.19); however,
an increase in hospital death was seen in patients with at
least moderate aortic regurgitation (Fig. 1).
Follow-up mortality
Thirty-day mortality occurred in 14 (4.3%) patients, with
only 1 occurring after discharge, which was attributed to
sudden death. This was significantly higher in patients
with moderate/severe postprocedural aortic regurgitation
than in those with absent or mild aortic regurgitation (38.5
vs. 2.9%, P< 0.001).
At a median clinical follow-up of 342 days (interquartile
range 93–485), all-cause mortality occurred in 57 (17.7%)
patients. Figure 1 shows the distribution of cardiovascular
and all-cause mortality according to postprocedural aortic
regurgitation grade. Table 5 summarizes the causes of
death during follow-up. All-cause death occurred in 10
(9.5%) patients without postprocedural aortic regurgita-
tion, in 40 (19.6%) patients with mild postprocedural
aortic regurgitation (P¼ 0.023 vs. no aortic regurgitation)
and in 7 (53.8%) patients with moderate/severe postpro-
cedural aortic regurgitation (P< 0.004 vs. mild aortic
regurgitation). Overall cardiovascular mortality occurred
in 36 (11.2%) patients: 3 (2.9%) in patients without
288 Journal of Cardiovascular Medicine 2015, Vol 16 No 4
Table 1 Baseline clinical characteristics according to postprocedural aortic regurgitation grade
Overall
(n¼322)
No aortic
regurgitation (n¼105)
Mild aortic
regurgitation (n¼204)
Moderate/severe aortic
regurgitation (n¼13) P-value
Age (years) 79.67 79.976.8 79.397.14 79.767.66 0.78
Male sex 165 (51.2%) 48 (45.7%) 111 (54.4%) 6 (46.2%) 0.32
BMI (kg/m2) 26.24.6 26.95.1 25.94.2 25.94.3 0.16
Hypertension 243 (75.5%) 82 (78.1%) 153 (75.0%) 8 (61.5%) 0.41
Hyperlipidemia 194 (60.2%) 68 (64.8%) 118 (57.8%) 8 (61.5%) 0.49
Diabetes mellitus 96 (29.8%) 39 (37.1%) 55 (27%) 2 (15.4%) 0.092
Smoker 11 (3.4%) 4 (3.8%) 6 (2.9%) 1 (7.7%) 0.63
Chronic kidney disease 105 (32.6%) 31 (29.5%) 70 (34.3%) 4 (30.8%) 0.68
Previous AMI 72 (22.4%) 19 (18.1%) 51 (25%) 2 (15.4%) 0.31
Previous PCI 69 (21.4%) 21 (20%) 45 (22.1%) 3 (23.1%) 0.90
Previous CABG 71 (22.0%) 20 (19%) 49 (24%) 2 (15.4%) 0.51
CAD 140 (44.3%) 50 (49%) 84 (41.8%) 6 (46.2%) 0.49
COPD 120 (37.3%) 38 (36.2%) 78 (38.2%) 4 (30.8%) 0.83
Previous pacemaker 29 (9%) 8 (7.6%) 20 (9.8%) 1 (7.7%) 0.80
Logistic EuroSCORE 24.016.9 21.160.8 25.460.5 25.221.4 0.09
STS score 9.59.3 9.910.1 8.17.8 12.59.3 0.14
NYHA class I or II 106 (33.1%) 36 (35%) 65 (31.9%) 5 (38.5%) 0.79
NYHA class III or IV 214 (66.9%) 67 (65%) 139 (68.1%) 8 (61.5%) 0.79
Angina 98 (31%) 35 (34.3%) 59 (29.2%) 4 (33.3%) 0.65
Syncope 59 (18.5%) 24 (23.3%) 31 (15.3%) 4 (30.8%) 0.11
AMI, acute myocardial infarction; CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; NYHA, New York
Heart Association; PCI, percutaneous coronary intervention.
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
postprocedural aortic regurgitation, 27 (13.2%) in patients
with mild postprocedural aortic regurgitation (P¼ 0.004
vs. no aortic regurgitation) and 6 (46.2%) in patients with
moderate/severe postprocedural aortic regurgitation
(P< 0.001 vs. no or mild postprocedural aortic regurgita-
tion).
Predictors of mortality
At multivariable analysis, postprocedural aortic regurgita-
tion [hazard ratio (HR)¼ 2.65 absent vs. present any grade,
95% confidence interval (CI)¼ 1.11–6.29; P¼ 0.027)],
BMI (HR¼ 0.878 for every 1U increase, 95%
CI¼ 0.814–0.947; P¼ 0.001), STS score (HR¼ 1.033 for
every 1U increase, 95% CI¼ 1.010–1.058; P¼ 0.005) and
LVEF (HR¼ 1.14 for every 5% decrease, 96%CI¼ 1.03–
1.26; P¼ 0.015) were found to be independent predictors
of midterm mortality (Table 6).
Impact of postprocedural aortic regurgitation on
midterm mortality
Kaplan–Meier curves for all-cause and cardiovascular
mortality according to postprocedural aortic regurgitation
grade are shown in Fig. 2. Actuarial all-cause mortality at 1
year was higher in patients with moderate/severe postpro-
cedural aortic regurgitation than in those with mild (33.3
vs. 13.7%; log-rank P¼ 0.02) and absent postprocedural
aortic regurgitation (9.8%; log-rank P¼ 0.002). Actuarial
all-cause mortality, however, was not different in patients
with mild and with absent aortic regurgitation (log-rank
P¼ 0.21) (Fig. 2a). Actuarial cardiovascular mortality was
significantly higher in patientswithmoderate/severe aortic
regurgitation than in those with absent (33.3 vs. 3.2%, log-
rank P< 0.0001) and mild aortic regurgitation (33.4 vs.
8.4%, log-rank P¼ 0.002). Actuarial cardiovascular
mortality was also significantly different in the mild aortic
regurgitation group comparedwith that in the absent aortic
regurgitation group (8.4 vs. 3.2%, log-rank P¼ 0.03)
(Fig. 2b).
Natural history of postprocedural aortic regurgitation
TTE was performed during follow-up at 30 days, 6
months, 1 year and after 1 year. Complete TTE data
were available for 136 patients, which were analyzed in
order to assess the natural history of postprocedural
aortic regurgitation.
Six months
Among the 44 (32.3%) patients without aortic regurgita-
tion at discharge, 34 (77.3%) patients remained free
from aortic regurgitation at 6-month follow-up, whereas
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Table 2 Baseline echocardiographic characteristics according to postprocedural aortic regurgitation grade
Overall
(n¼322)
No aortic
regurgitation (n¼105)
Mild aortic
regurgitation (n¼204)
Moderate/severe aortic
regurgitation (n¼13) P-value
LVEF 51.412.7 5311.5 50.613.2 49.615 0.25
LVEF <40% 46 (14.3%) 11 (10.5%) 31 (15.2%) 4 (30.8%) 0.11
Mean aortic gradient (mmHg) 53.315.0 52.015.6 54.515.3 50.411.3 0.31
Maximum aortic gradient (mmHg) 8622.0 82.419.6 88.324.0 81.517.5 0.07
Anatomic valve area (TEE, AVAcm2) 0.710.22 0.80.22 0.690.21 0.650.13 0.003
Aortic annulus diameter (mm)
Measured with CT 22.93.1 23.00.29 23.31.9 24.32.1 0.24
Measured with TEE 23.14.1 23.51.8 23.42.1 23.92.0 0.80
Measured with TTE 22.63.0 22.81.5 23.01.8 22.81.4 0.92
Any previous aortic regurgitation 247 (78.2%) 72 (70.6%) 165 (82.1%) 10 (76.9%) 0.08
LV end-diastolic diameter (mm) 52.17.5 50.56.3 52.97.9 56.59.5 0.035
LV end-systolic diameter (mm) 33.88.1 32.88.5 34.37.6 40.39.0 0.25
Any mitral regurgitation 268 (83.2%) 86 (81.9%) 172 (84.3%) 10 (76.9%) 0.71
AVA, aortic valve area; CT, computed tomography; LV, left ventricular; LVEF, left ventricular ejection fraction; TEE, transesophageal echocardiography; TTE, transthoracic
echocardiography.
Table 3 Procedural characteristics according to postprocedural aortic regurgitation grade
Overall
(n¼322)
No aortic
regurgitation (n¼105)
Mild aortic
regurgitation (n¼204)
Moderate/severe aortic
regurgitation (n¼13) P-value
Access
Femoral 261 (81.1%) 81 (77.1%) 169 (82.8%) 11 (84.6) 0.39
Apical 24 (7.4%) 11 (10.5%) 12 (5.9%) 1 (7.7%) 0.34
Subclavian 34 (10.6%) 11 (10.5%) 22 (10.8%) 1 (7.7%) 0.93
Aortic 3 (0.9%) 2 (1.9%) 1 (0.5%) 0 (0%) 0.44
Transcatheter valve type
CoreValve 128 (39.8%) 40 (38.1%) 84 (41.2%) 4 (30.8%) 0.69
26mm 47 (36.7%) 16 (40%) 30 (35.7%) 1 (25%) 0.79
29mm 81 (63.3%) 24 (60%) 54 (64.3%) 3 (75%) 0.62
Edwards 194 (60.2%) 65 (61.9%) 120 (58.8%) 9 (69.2%) 0.79
23mm 74 (38.1%) 21 (32.3%) 49 (40.8%) 4 (44.4%) 0.48
26mm 119 (61.3%) 43 (66.2%) 71 (59.2%) 5 (55.6%) 0.60
29mm 1 (0.5%) 1 (1.5%) 0 (0%) 0 (0%) 0.36
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progression to mild aortic regurgitation was seen in 10
(22.7%) patients. Of the 88 (64.7%) patients with mild
aortic regurgitation at discharge, 75 (85.2%) patients
remained stable, whereas aortic regurgitation resolved
in 12 (13.6%) patients and progressed to moderate/severe
in 1 (1.2%) patient. Of the four (2.9%) patients with
moderate/severe aortic regurgitation at discharge, two
remained stable, whereas aortic regurgitation resolved
in one (25%) patient and reduced to mild in 1 (25%)
patient at 6-month follow-up.
One year
At 1-year follow-up, 44/47 (93.6%) patients without aortic
regurgitation at 6 months remained stable, whereas pro-
gression to mild aortic regurgitation was observed in 3
(6.4%) patients. Of the 86 patients with mild aortic
regurgitation at 6 months, 77 (89.5%) remained stable,
whereas in 6 (7%) patients aortic regurgitation resolved
and in 3 (3.5%) patients worsened to moderate/severe.
Moderate/severe aortic regurgitation remained stable in
three patients. After the 1-year follow-up, postprocedural
aortic regurgitation worsened in only one patient, from
mild to severe, because of infective endocarditis in an
Edwards SAPIEN THV (cusp laceration with severe
central aortic regurgitation) that required a subsequent
second TAVI procedure (valve-in-valve).
Discussion
The main findings of the present study are as follows:
(1) Postprocedural aortic regurgitation was frequent and
occurred in 67.4% of patients (217). Among these,
aortic regurgitation was moderate/severe in only 6%
of patients (13/217).
290 Journal of Cardiovascular Medicine 2015, Vol 16 No 4
Table 4 Causes of overall in-hospital death according to postprocedural aortic regurgitation grade
In-hospital causes of death
Overall
[n¼13/322 (4.0%)]
No aortic
regurgitation
[n¼1/105 (0.9%)]
Mild aortic
regurgitation
[n¼7/20 (3.4%)]
Moderate/severe
aortic regurgitation
[n¼5/13 (38.5%)]
Aortic dissection 3 0 2 1
Cardiogenic shock 2 1 0 1
Multiorgan failure 2 0 1 1
Arrhythmia 2 0 1 1
Aortic annulus rupture 1 0 0 1
Retroperitoneal bleeding 1 0 1 0
Right ventricular failure 1 0 1 0
Interventricular septum rupture 1 0 1 0
Fig. 1
0%
1% 3.4%
38.5%
10%
20%
30%
40%
50%
60%
In-hospital mortality
No AR Mild AR Moderate/severe AR
Cardiovascular death Other cause of mortality
6.6%
6.4%
7.6%
13.2%
46.2%
2.9%
Cardiovascular and all-cause mortality according to postprocedural aortic regurgitation grade. AR, aortic regurgitation. P-value for trend <0.001.
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(2) Although uncommon, moderate/severe aortic regur-
gitation is associated with a significant impact on
early and midterm mortality.
(3) Even mild aortic regurgitation appears to be
associated with increased cardiovascular mortality.
(4) The severity of postprocedural aortic regurgitation
appears to remain stable during follow-up in the
majority of patients, irrespective of the THV
implanted.
Variable rates of postprocedural aortic regurgitation fol-
lowing TAVI have been reported in the literature.
Depending on the method of assessment (angiography
vs. echocardiography, quantitative vs. semiquantitative),
the reported incidence of postprocedural aortic regurgita-
tion varies between 40 and 67% for trivial to mild aortic
regurgitation22–24 and 7 and 20% for moderate-to-severe
aortic regurgitation.22–25 According to the VARC defi-
nition of aortic regurgitation, we reported a 67.4% inci-
dence of total postprocedural aortic regurgitation (of
which 94% was mild and 6% moderate/severe), in agree-
ment with the results from other studies.6,15,26–29 On the
other hand, we reported a 6% incidence of moderate/
severe postprocedural aortic regurgitation, which is lower
than the 4–17.2% incidence demonstrated by other
studies.6,15,26–29 This may reflect differences in the
definitions of aortic regurgitation applied (VARC vs.
non-VARC), the interventional technique used at each
institution and differences in the timing andmethod used
to assess postprocedural aortic regurgitation. Recent data
from large studies3,29 identified significant postproce-
dural aortic regurgitation (moderate/severe) as a predictor
of early and midterm mortality. This was also the case in
our study as this was associated with a worse outcome in
terms of survival free from overall and cardiovascular
mortality as compared with absent or mild postprocedural
aortic regurgitation. Aside from the clear influence of
moderate/severe postprocedural aortic regurgitation on
mortality, the impact of mild aortic regurgitation on
midterm outcome has yielded conflicting results in recent
literature.4,30 Such discrepancies may be related to the
challenges associated with both the echocardiographic
and angiographic identification and quantification of
postprocedural aortic regurgitation, which still remains
controversial and imprecise.31
In our study, even mild aortic regurgitation had a signifi-
cant impact onmidterm outcome as it was associated with
a higher cardiovascular mortality at follow-up as com-
pared with no aortic regurgitation. Previous TTE-based
studies32 have suggested that even mild postprocedural
aortic regurgitation may be clinically detrimental, a find-
ing that is difficult to explain physiologically. The reason
as to why mild postprocedural aortic regurgitation may
influence cardiovascular mortality remains unclear. A
possible explanation is that a hypertrophic left ventricle
that has been exposed to midterm pressure overload may
not be able to adapt abruptly to volume overload, even if
mild, especially if preprocedural aortic regurgitation had
not been present. Furthermore, recent studies33,34
showed that aortic regurgitation severity is underesti-
mated by TTE compared with cardiac MRI, so one
may speculate that at least part of these patients with
aortic regurgitation classified as mild may have had at
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Table 5 Causes of death during follow-up according to postprocedural aortic regurgitation grade
Cause of death
Overall
[n¼44/322 (13.6%)]
No aortic
regurgitation
[n¼8/105 (0.7%)]
Mild aortic
regurgitation
[n¼33/204 (16%)]
Moderate/severe
aortic regurgitation
[n¼3/13 (23%)]
Cardiovascular causes
Ischemic stroke 3 0 3 0
Hemorrhagic stroke 2 0 2 0
Malignant arrhythmia 1 0 1
Heart failure 7 0 6 1
Interventricular septum rupture 1 0 1
Myocardial infarction 3 2 0 1
Sudden death 8 0 8 0
Noncardiovascular causes
Multiorgan failure 3 2 1 0
Sepsis 4 1 2 1
Hepatorenal syndrome 1 0 1 0
Cancer 3 1 2 0
Subdural hematoma 1 0 1 0
Hepatic cirrhosis 2 0 2 0
Respiratory failure 3 1 2 0
Femoral fracture 1 0 1 0
Renal failure 1 1 0 0
Table 6 Predictors of midterm mortality at multivariable Cox
regression analysis
Variables
Univariate
P
Multivariate
P HR 95% CI
BMI (for every 1U increase) 0.001 0.001 0.87 0.81–0.94
STS score (for every 1U increase) 0.001 0.005 1.03 1.01–1.05
LVEF (for every 5% decrease) 0.001 0.015 1.14 1.03–1.26
Postprocedural aortic regurgitation
(absent vs. present any grade)
0.027 0.027 2.65 1.11–6.29
CI, confidence interval; HR, heart rate; LVEF, left ventricle ejection fraction.
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
least moderate aortic regurgitation. This finding could
help to explain the worse clinical outcome of these
patients with ‘mild’ aortic regurgitation. Therefore, the
potential incremental prognostic value of cardiac MRI
should be prospectively investigated in this setting. Fol-
lowing an accurate assessment, the complete elimination
of a postprocedural aortic regurgitation represents
another important goal in THV implantation procedures.
Mismatch of valve annulus and prosthesis diameter size,
aortic root calcification and suboptimal device implan-
tation have already been identified as major culprits for
postprocedural aortic regurgitation in a recent meta-
analysis.35 Undersizing of the THV to the annulus size
is a key reason for postprocedural aortic regurgitation.
Thus, precise annulus sizing and quantification of the
extent and location of calcification in the aortic root by
appropriate preprocedural 3D imaging are of great
importance in order to adequately size the THV and
prevent postprocedural aortic regurgitation.36–38 Along
with the preprocedural planning, postimplantation coun-
termeasures such as valve-in-valve implantation, valve
snaring and postdilatation may also be considered to
reduce moderate/severe postprocedural aortic regurgita-
tion (particularly after CoreValve implantation). On the
basis of the prognostic importance of mild aortic regur-
gitation shown in our study, we believe that it would
be reasonable to consider postdilatation in selected
patients with mild aortic regurgitation in whom clear
valve underexpansion is evident but should be avoided
in patients with severe asymmetrical calcification or left
ventricular outflow tract calcification. Although all these
periprocedural measures are certainly important in redu-
cing aortic regurgitation with standard devices, the pre-
liminary data from new-generationTHVs (with improved
subannular fixation designs or external space-filling
materials) are promising and suggest that residual post-
procedural aortic regurgitation may become an irrelevant
issue in the near future.39,40
Natural history of postprocedural aortic regurgitation
To date, limited information is available regarding the
natural history of postprocedural aortic regurgitation.
Among the 136 patients with complete echocardiographic
follow-up data, aortic regurgitation appeared to remain
stable from discharge to follow-up in the majority of
patients irrespective of the THV implanted. Our data
suggest that if change in aortic regurgitation does occur,
whether it is improvement or deterioration, this usually
tends to happen within the first 6 months. It appears that
from 6 months to 1 year, significant change in the degree
of aortic regurgitation is uncommon. This finding is
consistent with the 3-year data of the Placement of aortic
transcatheter valves trial32 demonstrating no significant
change in aortic regurgitation during follow-up among the
patients who underwent echocardiographic evaluation
after TAVI. Our data, however, are in contradiction to
the CoreValve U.S. Pivotal Trial in which 80% of patients
with moderate postprocedural aortic regurgitation at
1 month who survived to 1 year experienced a reduction
in the aortic regurgitation over time.41 The reason for this
may be related to the fact that both balloon-expandable
and self-expanding valves were implanted in our study
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and the high rate of postdilatation in CoreValve may have
negated this late effect. Echocardiographic evolution of
postprocedural aortic regurgitation at follow-up is shown
in Fig. 3.
Predictors of mortality
In previously published studies,13 significant post-TAVI
aortic regurgitation was identified as one of the predictors
of midterm mortality. Our results demonstrate similar
findings. On multivariable analysis, BMI, STS score and
LVEF were also identified as predictors of midterm
mortality. Given the advanced age of patients undergoing
TAVI, low BMI could represent a marker of cachexia and
thus an index of frailty. These patients may tolerate
poorly the potential complications associated with the
procedure. The type of bioprosthesis used for TAVI was
not identified as a predictor of midterm mortality con-
sistently with the results of a recent randomized trial42
that compared the self-expandable THV with the bal-
loon-expandable THV.
Study limitations
The present study reports a retrospective single-center
TAVI cohort of limited size and follow-up period. The
echocardiographic assessment of aortic regurgitation
severity may be operator dependent, and hence it might
have been more accurate to have a single operator or core
lab evaluate aortic regurgitation (postprocedure and
during follow-up) in order to maintain uniformity. Aortic
regurgitation assessment, however, was performed as per
guidelines and by an independent experienced echocar-
diographist. The mixed cohort of THV included in the
present analysis, although it may be perceived as a
limitation, reflects our everyday clinical practice.
Conclusion
Postprocedural aortic regurgitation is a frequent event
and has an adverse effect on early and midtermmortality.
This impact is higher with increasing grades of aortic
regurgitation, but it is present even in the case of mild
postprocedural aortic regurgitation compared with
absent. The present study confirms that every effort
(i.e. postdilatation, snaring, valve-in-valve implantation)
should be made to minimize the grade of postprocedural
aortic regurgitation with current devices through com-
prehensive preprocedural planning and meticulous pro-
cedural execution. New-generation THVs are needed to
address the issues of repositionability in order to facilitate
accurate placement and include additional features to
minimize postprocedural aortic regurgitation, which
should further improve TAVI outcomes.
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